Common Atrial Flutter and Macroreentrant and Multifocal Atrial Tachycardias¶
Chapter 257 | Part 12: Endocrinology
KEY CLINICAL POINTS¶
- Common atrial flutter is characterized by a macroreentrant circuit around the cavotricuspid isthmus (CTI), with typical ECG findings of sawtooth flutter waves in leads II, III, aVF, and positive P waves in V1/V2.
- Catheter ablation of the CTI is first-line therapy with >95% success rate, while antiarrhythmic drugs (e.g., sotalol, amiodarone) are used for rate control but have high recurrence rates.
- Multifocal atrial tachycardia (MAT) presents with ≥ 3 distinct P-wave morphologies, often in patients with chronic pulmonary disease, and is managed by treating underlying disease and avoiding beta-blockers.
- Anticoagulation is critical for atrial flutter to prevent thromboembolism, guided by CHADS-VASc score, with warfarin or DOACs preferred.
- Reverse typical flutter and lower-loop flutter are variants with different anatomical circuits, while atypical macroreentrant flutters involve scar-mediated reentry.
1. DEFINITION & OVERVIEW¶
Common atrial flutter (AFL) is a macroreentrant tachycardia characterized by a large anatomic reentry circuit, often involving scar tissue. Typical AFL is CTI-dependent, with counterclockwise rotation around the tricuspid annulus. Reverse typical flutter has clockwise rotation, and lower-loop flutter involves the low right atrial isthmus. Multifocal atrial tachycardia (MAT) is a distinct entity with multiple atrial foci.
Typical Atrial Flutter¶
| Feature | Typical AFL | Reverse Typical AFL | MAT |
|---|---|---|---|
| ECG Pattern | Negative flutter waves in inferior leads | Positive flutter waves in inferior leads | Irregular rhythm with ‡3 P-wave morphologies |
| Atrial Rate | 240–300 bpm | 240–300 bpm | 100–150 bpm |
| AV Conduction | 2:1 block (140–150 bpm) | 2:1 block (140–150 bpm) | Variable (often 2:1) |
| Underlying Mechanism | CTI-dependent macroreentry | CTI-dependent macroreentry | Multiple atrial foci with triggered activity |
1.1 ECG Features¶
Typical AFL shows sawtooth flutter waves in inferior leads (II, III, aVF) and positive P waves in V1/V2. Reverse typical flutter has inverted P waves in these leads. MAT exhibits irregular rhythms with ≥ 3 distinct P-wave morphologies.
1.2 Clinical Presentation¶
Patients may present with palpitations, dyspnea, chest pain, or syncope. Hemodynamic instability is rare but possible with WPW syndrome. MAT is often associated with chronic pulmonary disease and acute illnesses.
2. EPIDEMIOLOGY¶
Common in patients with atrial scarring from senescence, prior cardiac surgery, or atrial fibrillation. Right atrial flutter is more common than left. MAT is frequently seen in patients with chronic obstructive pulmonary disease (COPD) or acute illnesses.
2.1 Risk Factors¶
Atrial scarring, prior cardiac surgery, chronic pulmonary disease, electrolyte imbalances, and use of antiarrhythmics (e.g., amiodarone).
2.2 Demographics¶
Most common in middle-aged to elderly patients. MAT is more prevalent in patients with chronic lung disease or acute decompensation.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Macroreentrant AFL involves a large reentry circuit around the CTI, often with slow conduction through scar tissue. MAT results from multiple atrial foci with triggered activity. Antiarrhythmics like flecainide/propafenone can promote reentry in patients with AF.
3.1 Mechanisms¶
CTI-dependent macroreentry (typical AFL), scar-mediated reentry (atypical AFL), or multiple foci (MAT). Functional block or anatomical barriers (e.g., crista terminalis) may contribute to reentry.
3.2 Molecular Basis¶
Abnormal ion channel function in atrial tissue, altered conduction velocities, and enhanced automaticity in foci. Antiarrhythmics modulate ion currents to disrupt reentry.
4. CLINICAL FEATURES¶
Symptoms include palpitations, dyspnea, chest discomfort, and syncope. Signs may include tachycardia, hypotension, or signs of heart failure. MAT is often associated with respiratory distress and hypoxia.
4.1 Complications¶
Thromboembolism, heart failure, and progression to atrial fibrillation. MAT may lead to pulmonary hypertension and right ventricular dysfunction.
4.2 Differential Diagnosis¶
Ventricular tachycardia, preexcited tachycardia, and atrial fibrillation. MAT must be distinguished from AF using P-wave morphology and isoelectric intervals.
5. INVESTIGATIONS & DIAGNOSIS¶
ECG is the primary diagnostic tool. Typical AFL shows sawtooth flutter waves, while MAT has ≥ 3 distinct P-wave morphologies. Echocardiography may reveal structural heart disease.
5.1 Diagnostic Criteria¶
ECG findings: sawtooth flutter waves (AFL), ≥ 3 P-wave morphologies (MAT), or irregular rhythm with no isoelectric intervals (AF).
5.2 Algorithms¶
Adenosine or vagal maneuvers for stable PSVT. Cardioversion for unstable patients. Electrophysiologic studies confirm reentry circuits for ablation.
6. MANAGEMENT & TREATMENT¶
Acute management includes adenosine, beta-blockers, or calcium channel blockers. Long-term therapy involves catheter ablation (first-line) or antiarrhythmics. Anticoagulation is critical for thromboembolism prevention.
6.1 Acute Treatment¶
Adenosine (12–24 mg IV) for stable patients. Verapamil/diltiazem (5–10 mg IV) for rate control. Cardioversion for hemodynamic instability.
6.2 Long-Term Therapy¶
Catheter ablation of CTI (success rate >95%). Antiarrhythmics (e.g., sotalol, amiodarone) for rate control. Anticoagulation with warfarin/DOACs for AF risk.
6.3 Special Considerations¶
Avoid beta-blockers in severe pulmonary disease. Amiodarone may be used for MAT but with caution for pulmonary fibrosis. Monitor for recurrence post-ablation.
7. PROGNOSIS & COMPLICATIONS¶
Excellent with ablation, but recurrence rates are ~50% without intervention. Complications include thromboembolism, heart failure, and progression to AF. MAT is associated with higher mortality in severe pulmonary disease.
7.1 Recurrence¶
AFL recurrence rates are ~50% without ablation. MAT may resolve with treatment of underlying disease.
7.2 Thromboembolism¶
Risk is similar to AF but lower than ventricular tachycardia. Anticoagulation reduces stroke risk in high-risk patients.
8. SPECIAL CONSIDERATIONS¶
Pregnancy: Avoid amiodarone; use rate control agents. Pediatrics: MAT is rare but may occur in congenital heart disease. Elderly: Monitor for drug interactions and renal function.
8.1 Pregnancy¶
Avoid amiodarone; use calcium channel blockers or digoxin for rate control. Monitor for fetal distress.
8.2 Elderly Patients¶
Use lower drug doses; monitor for bradycardia and renal impairment. Consider ablation for recurrent episodes.
9. KEY POINTS & CLINICAL PEARLS¶
- Typical AFL is CTI-dependent with sawtooth flutter waves. 2. Adenosine is first-line for stable PSVT. 3. Catheter ablation is first-line for long-term management. 4. MAT is managed by treating underlying disease and avoiding beta-blockers. 5. Anticoagulation is critical for thromboembolism prevention in AFL.